Indications
Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
Composition
- Active substance
- anifrolumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Saphnelo
- Active substance
- anifrolumab
- ATC code
- L04AG11
- Therapeutic area
- Lupus Erythematosus, Systemic
- Marketing authorisation holder
- AstraZeneca AB
- Status
- Authorised